Physicians

For information about YM BioSciences' products and ongoing clinical studies, please click the appropriate link below.

CYT387

  • Indication: Hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders
  • JAK 1/2 small molecule inhibitor
  • Ongoing Phase I/II and Phase II clinical studies


Nimotuzumab

  • Indication: Cancer
  • Monoclonal antibody
  • Ongoing Phase I, Phase II and Phase III clinical studies for lung cancer, pediatric and adult glioma, esophageal cancer, pancreatic cancer, prostate cancer, gastric cancer, cervical cancer, hepatic carcinoma and breast cancer
  • Approved for sale in certain countries
  • Nimotuzumab has been made available to patients through compassionate use or expanded access programs in many countries including the US, Canada and Europe.


CYT997